Lalit Kumar is an Assistant Professor in the Department of Pharmaceutics at the National Institute of Pharmaceutical Education and Research, Hajipur, Vaishali, Bihar, India. His area of research includes the development of nanocarriers for drug-targeting tumor cells in the colon, brain, breast, and lungs. Dr. Dalapathi Gugulothu working as Assistant professor, Department of Pharmaceutics , Delhi Institute of Pharmaceutical Sciences and Research, Delhi Pharmaceutical Sciences and Research University , New Delhi. Dr. Sushama Talegaonkar is an Associate Professor at the Department of Pharmaceutics, Delhi Pharmaceutical Sciences and Research University, India. She has approximately 21 years of experience, and has published more than 220 research papers in high impact international journals. Besides this, she has coauthored 6 books and authored 15 chapters in international reference books. Recently, she received the Professor C. J. Shishoo Award for Best Research. Her research paper titled “Development and bioavailability assessment of ramipril nanoemulsion formulation” has received the most cited research paper award on behalf of Elsevier and the board of European Journal of Pharmaceutics and Biopharmaceutics. She was awarded the prestigious Motan Devi Dandiya Biennial Prize for best publication in Pharmaceutical Sciences for the period 2010–11. Dr. Talegaonkar is actively involved in developing a wide variety of smart and functionalized nanodrug delivery systems for targeted anticancer drug delivery.

Select Guide Rating

• Part I. Tissue-Specific Targets1. Brain-Specific Regulatory T Cell (Treg) Mediators2. Liver-Specific Regulatory T Cell Mediators3. Lung-Specific Regulatory T Cell Mediators4. Adrenal Gland-Specific Regulatory T Cell Mediators5. Lymph Node-Specific Regulatory T Cell Mediators6. Skin-Specific Regulatory T Cell Mediators7. Bone-Specific Regulatory T Cell Mediators8. Colon-Specific Regulatory T Cell Mediators9. Breast-Specific Regulatory T Cell MediatorsPart II. Tumor Tissue-Specific Targets10. Molecular Targets for Liver Cancer11. Molecular Targets for Gastric Cancer12. Molecular Targets for Breast Cancer13. Molecular Targets for Ovarian Cancer14. Molecular Targets in Prostate Cancer15. Molecular Targets in Colon Cancer16. Molecular Targets in Lung Cancer17. Molecular Targets in Blood CancerPart III. Advanced Therapeutic Approaches18. Human Genetic Mutation-Based Targeting19. Microbiome in Cancer Immunotherapy and Cancer Progression20. Precision Medicine21. Future Directions and Challenges in Cancer Targeting Therapies

Lalit Kumar is an Assistant Professor in the Department of Pharmaceutics at the National Institute of Pharmaceutical Education and Research, Hajipur, Vaishali, Bihar, India. His area of research includes the development of nanocarriers for drug-targeting tumor cells in the colon, brain, breast, and lungs. Dr. Dalapathi Gugulothu working as Assistant professor, Department of Pharmaceutics , Delhi Institute of Pharmaceutical Sciences and Research, Delhi Pharmaceutical Sciences and Research University , New Delhi. Dr. Sushama Talegaonkar is an Associate Professor at the Department of Pharmaceutics, Delhi Pharmaceutical Sciences and Research University, India. She has approximately 21 years of experience, and has published more than 220 research papers in high impact international journals. Besides this, she has coauthored 6 books and authored 15 chapters in international reference books. Recently, she received the Professor C. J. Shishoo Award for Best Research. Her research paper titled “Development and bioavailability assessment of ramipril nanoemulsion formulation” has received the most cited research paper award on behalf of Elsevier and the board of European Journal of Pharmaceutics and Biopharmaceutics. She was awarded the prestigious Motan Devi Dandiya Biennial Prize for best publication in Pharmaceutical Sciences for the period 2010–11. Dr. Talegaonkar is actively involved in developing a wide variety of smart and functionalized nanodrug delivery systems for targeted anticancer drug delivery.

Select Guide Rating

• Part I. Tissue-Specific Targets1. Brain-Specific Regulatory T Cell (Treg) Mediators2. Liver-Specific Regulatory T Cell Mediators3. Lung-Specific Regulatory T Cell Mediators4. Adrenal Gland-Specific Regulatory T Cell Mediators5. Lymph Node-Specific Regulatory T Cell Mediators6. Skin-Specific Regulatory T Cell Mediators7. Bone-Specific Regulatory T Cell Mediators8. Colon-Specific Regulatory T Cell Mediators9. Breast-Specific Regulatory T Cell MediatorsPart II. Tumor Tissue-Specific Targets10. Molecular Targets for Liver Cancer11. Molecular Targets for Gastric Cancer12. Molecular Targets for Breast Cancer13. Molecular Targets for Ovarian Cancer14. Molecular Targets in Prostate Cancer15. Molecular Targets in Colon Cancer16. Molecular Targets in Lung Cancer17. Molecular Targets in Blood CancerPart III. Advanced Therapeutic Approaches18. Human Genetic Mutation-Based Targeting19. Microbiome in Cancer Immunotherapy and Cancer Progression20. Precision Medicine21. Future Directions and Challenges in Cancer Targeting Therapies

Lalit Kumar is an Assistant Professor in the Department of Pharmaceutics at the National Institute of Pharmaceutical Education and Research, Hajipur, Vaishali, Bihar, India. His area of research includes the development of nanocarriers for drug-targeting tumor cells in the colon, brain, breast, and lungs. Dr. Dalapathi Gugulothu working as Assistant professor, Department of Pharmaceutics , Delhi Institute of Pharmaceutical Sciences and Research, Delhi Pharmaceutical Sciences and Research University , New Delhi. Dr. Sushama Talegaonkar is an Associate Professor at the Department of Pharmaceutics, Delhi Pharmaceutical Sciences and Research University, India. She has approximately 21 years of experience, and has published more than 220 research papers in high impact international journals. Besides this, she has coauthored 6 books and authored 15 chapters in international reference books. Recently, she received the Professor C. J. Shishoo Award for Best Research. Her research paper titled “Development and bioavailability assessment of ramipril nanoemulsion formulation” has received the most cited research paper award on behalf of Elsevier and the board of European Journal of Pharmaceutics and Biopharmaceutics. She was awarded the prestigious Motan Devi Dandiya Biennial Prize for best publication in Pharmaceutical Sciences for the period 2010–11. Dr. Talegaonkar is actively involved in developing a wide variety of smart and functionalized nanodrug delivery systems for targeted anticancer drug delivery.

Select Guide Rating

• Part I. Tissue-Specific Targets1. Brain-Specific Regulatory T Cell (Treg) Mediators2. Liver-Specific Regulatory T Cell Mediators3. Lung-Specific Regulatory T Cell Mediators4. Adrenal Gland-Specific Regulatory T Cell Mediators5. Lymph Node-Specific Regulatory T Cell Mediators6. Skin-Specific Regulatory T Cell Mediators7. Bone-Specific Regulatory T Cell Mediators8. Colon-Specific Regulatory T Cell Mediators9. Breast-Specific Regulatory T Cell MediatorsPart II. Tumor Tissue-Specific Targets10. Molecular Targets for Liver Cancer11. Molecular Targets for Gastric Cancer12. Molecular Targets for Breast Cancer13. Molecular Targets for Ovarian Cancer14. Molecular Targets in Prostate Cancer15. Molecular Targets in Colon Cancer16. Molecular Targets in Lung Cancer17. Molecular Targets in Blood CancerPart III. Advanced Therapeutic Approaches18. Human Genetic Mutation-Based Targeting19. Microbiome in Cancer Immunotherapy and Cancer Progression20. Precision Medicine21. Future Directions and Challenges in Cancer Targeting Therapies